Atorvastatin-induced prolonged cholestasis with bile duct damage

Clinical Drug Investigation

Volumn 30, Issue 3, 2010, Pages 205-209

  Merli, Manuela ^a   Bragazzi, Maria Consiglia ^a,b   Giubilo, Federica ^a   Callea, Francesco ^c   Attili, Adolfo F ^a   Alvaro, Domenico ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Polo Pontino   (Italy)

^c BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BILIRUBIN; ENALAPRIL; INSULIN; URSODEOXYCHOLIC ACID;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILE DUCT INJURY; BILIRUBIN BLOOD LEVEL; CASE REPORT; CHOLESTATIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; DRUG WITHDRAWAL; DYSLIPIDEMIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAUNDICE; LIVER BIOPSY; MALE; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; STEATORRHEA; URINE COMPOSITION DISORDER;

AGED; ANTICHOLESTEREMIC AGENTS; BILE DUCTS; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS; CHOLESTASIS; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; MALE; PYRROLES; URSODEOXYCHOLIC ACID;

EID: 77249100776     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11531660-000000000-00000     Document Type: Article

References (25)

1. Yusuf S, Lonn E, Bosch J. Lipid lowering for primary prevention. Lancet 2009; 373: 1152-1155
2. Onusko E. Statins and elevated liver tests: what's the fuss? J Fam Pract 2008; 57 (7): 449-452
3. Hussaini SH, Farrington EA. Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 2007; 6 (6): 673-684
4. Wierzbicki AS. Atorvastatin. Expert Opin Pharmacother 2001; 2 (5): 819-830
5. Recto 2nd CS, Acosta S, Dobs A. Comparison of the efficacy and tolerability of simvastatin and atorvastatin in the treatment of hypercholesterolemia. Clin Cardiol 2000; 23 (9): 682-688
6. Clarke AT, Mills PR. Atorvastatin associated liver disease. Dig Liver Dis 2006; 38 (10): 772-777
7. Abourjaily HM, Alsheikh-Ali AA, Karas RH. Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin. Am J Cardiol 2003 Apr 15; 91 (8): 999-1002
8. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001; 61 (12): 1835-1881
9. Yee HS, Fong NT. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias. Ann Pharmacother 1998; 32 (10): 1030-1043
10. Black DM, Bakker-Arkema RG, Nawrocki JW. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor. Arch Intern Med 1998 Mar 23; 158 (6): 577-584
11. Newman CB, Palmer G, Silbershatz H, et al. Safety of atorvastatin derived from analysis of 44 completed trials in 9,416 patients. Am J Cardiol 2003 Sep 15; 92 (6): 670-676
12. Rahier JF, Rahier J, Leclercq I, et al. Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report. Acta Gastroenterol Belg 2008; 71 (3): 318-320
13. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006 Apr 17; 97 (8A): 44C-51C
14. Suzuki A, Yuen N, Walsh J, et al. Co-medications modulating liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. Clin Gastroenterol Hepatol 2009; 7 (8): 882-888
15. Arca M. Atorvastatin: a safety and tolerability profile. Drugs 2007; 67 Suppl. 1: 63-69
16. Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46 (3): 776-784
17. Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006; 44 (6): 1581-1588
18. Jiménez-Alonso J, Osorio JM, Gutiérrez-Cabello F, et al. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med 1999; 159 (15): 1811-1812
19. De Castro ML, Hermo JA, Baz A, et al. Acute cholestatic hepatitis after atorvastatin reintroduction. Gastroenterol Hepatol 2006; 29 (1): 21-24
20. Ridruejo E, Mandó OG. Acute cholestatic hepatitis after reinitiating treatment with atorvastatin. J Hepatol 2002; 37 (1): 165-166
21. Armitage J. The safety of statins in clinical practice. Lancet 2007 Nov 24; 370 (9601): 1781-1790
22. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003 Jul 31; 349 (5): 474-485
23. Bénichou C. Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990; 11 (2): 272-276
24. Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26 (3): 664-669
25. Naranjo CA, Busto U, Sellers EM, et al. A reliable method for estimating the probability of adverse drug reactions. Clin Pharmac Ther 1981; 30: 239-245